Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
Authors:
Open Access
- 1 April 2013
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (15) , 10805-10818
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibitionNutrition, Metabolism and Cardiovascular Diseases, 2011
- Role of the C-terminal domain of PCSK9 in degradation of the LDL receptorsJournal of Lipid Research, 2011
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]Journal of Lipid Research, 2011
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brainJournal of Lipid Research, 2010
- Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domainMolecular Genetics and Metabolism, 2010
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein UptakeJournal of Biological Chemistry, 2010
- Cargo- and adaptor-specific mechanisms regulate clathrin-mediated endocytosisJournal of Cell Biology, 2010
- A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9Molecular Genetics and Metabolism, 2010
- Mechanism for Amyloid Precursor-like Protein 2 Enhancement of Major Histocompatibility Complex Class I Molecule DegradationJournal of Biological Chemistry, 2009
- Pathways and mechanisms of endocytic recyclingNature Reviews Molecular Cell Biology, 2009